Table 3.
Scenario | Description | References |
---|---|---|
Scenario 1 | Assumed lower vaccine coverage rates (47.6% for Denmark, 29.5% for Norway, and 50% for Sweden, average coverage from seasons 2014/15 to 2018/19) | [64,65,77,78,79,80,81] |
Scenario 2 (2.1 to 2.5) |
Conducted separate analyses for seasons 2014/15 to 2018/19 (5 seasons before COVID-19 pandemic) with influenza strain circulation for each season | [67,68,69,70,71,72,73,74,75,76,77,78,79,80,81] |
Scenario 3 | aQIV VE estimated using only effectiveness evidence from observational studies (using rVE for aTIV vs. SD-TIV from Coleman et al. [13.9%]) [41] | [41] |
Scenario 4 (4.1 to 4.2) |
Used lower (36% for H1N1, −6% for H3N2, and 33% for subtype B) and upper (78% for H1N1, 45% for H3N2, and 79% for subtype B) bounds of the 95% CI for SD-QIV VE | [39] |
Scenario 5 (5.1 to 5.2) |
Used lower and upper bounds of the 95% CI for rVE of HD-QIV vs. SD-QIV (9.7–36.5%) and aQIV vs. HD-QIV (−2.5–8.9%) | [40,41] |
Scenario 6 (6.1 to 6.2) |
Varied the management costs of all IRCs (outpatient and hospitalizations) by ±30% | NA |
Scenario 7 | Removed HF from the model | NA |
aQIV: Adjuvanted quadrivalent influenza vaccine; HD-QIV: High-dose quadrivalent influenza vaccine; HF: Heath failure; IRC: Influenza-related complications; SD-QIV: Standard-dose quadrivalent influenza vaccine; rVE: Relative vaccine effectiveness; VE: Vaccine effectiveness.